Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Dec 24, 2019 at 10:05 AM EST

Will Microbot Medical’s Robotic Surgery System Be a Big Hit?

Microbot Medical shares made a massive gain on Tuesday after the company revealed its Liberty system, which would be the…

Chris Lange | Dec 24, 2019 at 9:40 AM EST

Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics

NewLink Genetics shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with…

Paul Ausick | Dec 24, 2019 at 7:55 AM EST

Allergan Gets FDA Approval for Migraine Treatment

The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain…

Chris Lange | Dec 23, 2019 at 11:00 AM EST

The Top Biopharma Calendar Events to Watch Going Into 2020

Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to…

Chris Lange | Dec 23, 2019 at 10:20 AM EST

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for…

Chris Lange | Dec 23, 2019 at 9:45 AM EST

Why This Schizophrenia Treatment Approval Is Such a Big Deal

Intra-Cellular Therapy shares practically doubled on Monday after the firm announced that the FDA has approved Caplyta for the treatment…

Chris Lange | Dec 20, 2019 at 11:45 AM EST

The First Ebola Vaccine Has Been Approved in the US

NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval…

Chris Lange | Dec 20, 2019 at 10:40 AM EST

Is Stealth Bio Done After Mitochondrial Myopathy Study?

Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with…

Jon C. Ogg | Dec 19, 2019 at 1:40 PM EST

Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain

This Wedbush analyst sees close to 200% in potential upside in Paratek Pharmaceuticals beyond the massive one-day gain on Thursday.

Jon C. Ogg | Dec 19, 2019 at 10:25 AM EST

BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 2020

The U.S. Department of Health and Human Services has awarded Paratek Pharmaceuticals a pact to support development of its treatment…

Jon C. Ogg | Dec 18, 2019 at 5:24 PM EST

Gene Sequencing Merger May Be the Oddest Monopoly and Antitrust Case Ever

When most investors and consumers think of antitrust issues and monopolies, they probably think of big giant multinational companies with…

Chris Lange | Dec 18, 2019 at 11:10 AM EST

Meet the Newest Collaboration in the Fight Against Sickle Cell Disease

Syros Pharma and Global Blood Therapeutics shares were on the move on Wednesday after the companies announced a collaboration to…

Chris Lange | Dec 18, 2019 at 10:05 AM EST

Is Solid Biosciences in Trouble After This Duchenne Muscular Dystrophy Update?

Solid Biosciences shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy.

Chris Lange | Dec 17, 2019 at 1:00 PM EST

Why This Multiple Sclerosis Study’s Positive Results May Not Be Enough

Adamas Pharma shares dropped sharply on Tuesday after the firm reported results from its late-stage multiple sclerosis study.

Chris Lange | Dec 17, 2019 at 12:15 PM EST

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support…

1 … 74 75 76 77 78 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Will Microbot Medical’s Robotic Surgery System Be a Big Hit?

Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics

Allergan Gets FDA Approval for Migraine Treatment

The Top Biopharma Calendar Events to Watch Going Into 2020

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Why This Schizophrenia Treatment Approval Is Such a Big Deal

The First Ebola Vaccine Has Been Approved in the US

Is Stealth Bio Done After Mitochondrial Myopathy Study?

Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain

BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 2020

Gene Sequencing Merger May Be the Oddest Monopoly and Antitrust Case Ever

Meet the Newest Collaboration in the Fight Against Sickle Cell Disease

Is Solid Biosciences in Trouble After This Duchenne Muscular Dystrophy Update?

Why This Multiple Sclerosis Study’s Positive Results May Not Be Enough

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

Nobody Warned This 72-Year-Old His First RMD Would Cost an Extra $19,000 in Tax

T. Rowe Price Launches Multi-Crypto ETF Including Bitcoin, Ethereum, and XRP

Billionaire Investor Bill Ackman’s Top 5 Bets: Buy, Hold, or Steer Clear?

Nobody Warned This 72-Year-Old His First RMD Would Cost an Extra $19,000 in Tax

A 68-Year-Old With $850,000 in a Traditional IRA Is Sitting on a Six-Figure Tax Bill. Here's How Retirees Shrink It.

Nobody Warned This 72-Year-Old His First RMD Would Cost an Extra $19,000 in Tax

T. Rowe Price Launches Multi-Crypto ETF Including Bitcoin, Ethereum, and XRP

Health and Healthcare Articles

All Health and Healthcare Articles

Will Microbot Medical’s Robotic Surgery System Be a Big Hit?

Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics

Allergan Gets FDA Approval for Migraine Treatment

The Top Biopharma Calendar Events to Watch Going Into 2020

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Why This Schizophrenia Treatment Approval Is Such a Big Deal

The First Ebola Vaccine Has Been Approved in the US

Is Stealth Bio Done After Mitochondrial Myopathy Study?

Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain

BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 2020

Gene Sequencing Merger May Be the Oddest Monopoly and Antitrust Case Ever

Meet the Newest Collaboration in the Fight Against Sickle Cell Disease

Is Solid Biosciences in Trouble After This Duchenne Muscular Dystrophy Update?

Why This Multiple Sclerosis Study’s Positive Results May Not Be Enough

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

Nobody Warned This 72-Year-Old His First RMD Would Cost an Extra $19,000 in Tax

T. Rowe Price Launches Multi-Crypto ETF Including Bitcoin, Ethereum, and XRP

Billionaire Investor Bill Ackman’s Top 5 Bets: Buy, Hold, or Steer Clear?

Featured Reads

Nobody Warned This 72-Year-Old His First RMD Would Cost an Extra $19,000 in Tax

A 68-Year-Old With $850,000 in a Traditional IRA Is Sitting on a Six-Figure Tax Bill. Here's How Retirees Shrink It.